Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Calcif Tissue Int. 2013 Mar 21;93(1):1–14. doi: 10.1007/s00223-013-9724-8

Figure 2.

Figure 2

Example of a cost-effectiveness acceptability curve.

This graph shows the probability of an osteoporotic treatment being cost-effective compared with no treatment in patients aged 70 years with prevalent vertebral fractures, as a function of the decision-maker’s willingness-to-pay per one QALY [108].

The curve was estimated from probabilistic sensitivity analyses where most parameters (such as therapeutic effect, fracture risk, cost, and disutility) were assigned a probability distribution (e.g. normal or uniform distribution) and values from each distribution were randomly selected during a predefined number of simulations.